Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia
Background: Number of reports linked Telogen effluvium to coronavirus disease 2019 (COVID-19) infection. However, data about Telogen effluvium after COVID-19 vaccination are limited. Objectives: To estimate prevalence of Telogen effluvium among those who received COVID-19 vaccination. Methods: A cro...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=10;spage=6056;epage=6060;aulast=Alharbi |
| _version_ | 1811184019851706368 |
|---|---|
| author | Mana Alharbi |
| author_facet | Mana Alharbi |
| author_sort | Mana Alharbi |
| collection | DOAJ |
| description | Background: Number of reports linked Telogen effluvium to coronavirus disease 2019 (COVID-19) infection. However, data about Telogen effluvium after COVID-19 vaccination are limited. Objectives: To estimate prevalence of Telogen effluvium among those who received COVID-19 vaccination. Methods: A cross-sectional study was performed during July 2021. Adults who received one of recognized COVID-19 vaccine irrespective of previous COVID-19 infection were asked to fill a questionnaire. Results: The majority of participants were females (90.3%). The most common age group was between 21 and 30 years (51.9%). Out of 991 participants who were included in the current analysis, 670 (67.6%) reported post-vaccination hair fall. The probable causes of post-vaccination hair fall were vaccine-related in 185 (27.6%) participants, other causes in 326 (48.7%) participants, and unclear in 326 (48.7%) participants. Post-vaccination hair fall was significantly higher among females compared with males (68.5% versus 57.9%, P = 0.036), those who did not suffer compared with those who suffered from hair fall before vaccination (72.1% versus 63.4%, P = 0.003), and those who did not report compared with those who reported preexisting conditions that might be related to hair fall (74.5% versus 57.3%, P < 0.001). Conclusion: We are reporting a high prevalence of post-vaccination hair fall, which affected approximately two-thirds of participants who received COVID-19 vaccines. Only 28% of these participants were apparently vaccine related. The role of COVID-19 infection and stress caused by infection and vaccine cannot be excluded. Primary care physician and dermatologist need to consider the possibility of COVID-19 vaccine as a potential cause of hair loss. |
| first_indexed | 2024-04-11T13:06:19Z |
| format | Article |
| id | doaj.art-98ca4170eed74b3b90165b0f3c5d4be2 |
| institution | Directory Open Access Journal |
| issn | 2249-4863 |
| language | English |
| last_indexed | 2024-04-11T13:06:19Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Family Medicine and Primary Care |
| spelling | doaj.art-98ca4170eed74b3b90165b0f3c5d4be22022-12-22T04:22:45ZengWolters Kluwer Medknow PublicationsJournal of Family Medicine and Primary Care2249-48632022-01-0111106056606010.4103/jfmpc.jfmpc_377_22Telogen effluvium after COVID-19 vaccination among public in Saudi ArabiaMana AlharbiBackground: Number of reports linked Telogen effluvium to coronavirus disease 2019 (COVID-19) infection. However, data about Telogen effluvium after COVID-19 vaccination are limited. Objectives: To estimate prevalence of Telogen effluvium among those who received COVID-19 vaccination. Methods: A cross-sectional study was performed during July 2021. Adults who received one of recognized COVID-19 vaccine irrespective of previous COVID-19 infection were asked to fill a questionnaire. Results: The majority of participants were females (90.3%). The most common age group was between 21 and 30 years (51.9%). Out of 991 participants who were included in the current analysis, 670 (67.6%) reported post-vaccination hair fall. The probable causes of post-vaccination hair fall were vaccine-related in 185 (27.6%) participants, other causes in 326 (48.7%) participants, and unclear in 326 (48.7%) participants. Post-vaccination hair fall was significantly higher among females compared with males (68.5% versus 57.9%, P = 0.036), those who did not suffer compared with those who suffered from hair fall before vaccination (72.1% versus 63.4%, P = 0.003), and those who did not report compared with those who reported preexisting conditions that might be related to hair fall (74.5% versus 57.3%, P < 0.001). Conclusion: We are reporting a high prevalence of post-vaccination hair fall, which affected approximately two-thirds of participants who received COVID-19 vaccines. Only 28% of these participants were apparently vaccine related. The role of COVID-19 infection and stress caused by infection and vaccine cannot be excluded. Primary care physician and dermatologist need to consider the possibility of COVID-19 vaccine as a potential cause of hair loss.http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=10;spage=6056;epage=6060;aulast=Alharbicovid-19 vaccinehair fallsaudi arabiatelogen effluvium |
| spellingShingle | Mana Alharbi Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia Journal of Family Medicine and Primary Care covid-19 vaccine hair fall saudi arabia telogen effluvium |
| title | Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia |
| title_full | Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia |
| title_fullStr | Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia |
| title_full_unstemmed | Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia |
| title_short | Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia |
| title_sort | telogen effluvium after covid 19 vaccination among public in saudi arabia |
| topic | covid-19 vaccine hair fall saudi arabia telogen effluvium |
| url | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=10;spage=6056;epage=6060;aulast=Alharbi |
| work_keys_str_mv | AT manaalharbi telogeneffluviumaftercovid19vaccinationamongpublicinsaudiarabia |